BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 38252443)

  • 1. Diagnostic Accuracy of a Plasma Phosphorylated Tau 217 Immunoassay for Alzheimer Disease Pathology.
    Ashton NJ; Brum WS; Di Molfetta G; Benedet AL; Arslan B; Jonaitis E; Langhough RE; Cody K; Wilson R; Carlsson CM; Vanmechelen E; Montoliu-Gaya L; Lantero-Rodriguez J; Rahmouni N; Tissot C; Stevenson J; Servaes S; Therriault J; Pascoal T; Lleó A; Alcolea D; Fortea J; Rosa-Neto P; Johnson S; Jeromin A; Blennow K; Zetterberg H
    JAMA Neurol; 2024 Mar; 81(3):255-263. PubMed ID: 38252443
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnostic accuracy of the plasma ALZpath pTau217 immunoassay to identify Alzheimer's disease pathology.
    Ashton NJ; Brum WS; Di Molfetta G; Benedet AL; Arslan B; Jonatis E; Langhough RE; Cody K; Wilson R; Carlsson CM; Vanmechelen E; Montoliu-Gaya L; Lantero-Rodriguez J; Rahmouni N; Tissot C; Stevenson J; Servaes S; Therriault J; Pascoal T; Lleó A; Alcolea D; Fortea J; Rosa-Neto P; Johnson S; Jeromin A; Blennow K; Zetterberg H
    medRxiv; 2023 Jul; ():. PubMed ID: 37502842
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combining plasma Aβ and p-tau217 improves detection of brain amyloid in non-demented elderly.
    Niimi Y; Janelidze S; Sato K; Tomita N; Tsukamoto T; Kato T; Yoshiyama K; Kowa H; Iwata A; Ihara R; Suzuki K; Kasuga K; Ikeuchi T; Ishii K; Ito K; Nakamura A; Senda M; Day TA; Burnham SC; Iaccarino L; Pontecorvo MJ; Hansson O; Iwatsubo T
    Alzheimers Res Ther; 2024 May; 16(1):115. PubMed ID: 38778353
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders.
    Palmqvist S; Janelidze S; Quiroz YT; Zetterberg H; Lopera F; Stomrud E; Su Y; Chen Y; Serrano GE; Leuzy A; Mattsson-Carlgren N; Strandberg O; Smith R; Villegas A; Sepulveda-Falla D; Chai X; Proctor NK; Beach TG; Blennow K; Dage JL; Reiman EM; Hansson O
    JAMA; 2020 Aug; 324(8):772-781. PubMed ID: 32722745
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prediction of Longitudinal Cognitive Decline in Preclinical Alzheimer Disease Using Plasma Biomarkers.
    Mattsson-Carlgren N; Salvadó G; Ashton NJ; Tideman P; Stomrud E; Zetterberg H; Ossenkoppele R; Betthauser TJ; Cody KA; Jonaitis EM; Langhough R; Palmqvist S; Blennow K; Janelidze S; Johnson SC; Hansson O
    JAMA Neurol; 2023 Apr; 80(4):360-369. PubMed ID: 36745413
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of Plasma Phosphorylated Tau217 for Differentiation Between Alzheimer Disease and Frontotemporal Lobar Degeneration Subtypes Among Patients With Corticobasal Syndrome.
    VandeVrede L; La Joie R; Thijssen EH; Asken BM; Vento SA; Tsuei T; Baker SL; Cobigo Y; Fonseca C; Heuer HW; Kramer JH; Ljubenkov PA; Rabinovici GD; Rojas JC; Rosen HJ; Staffaroni AM; Boeve BF; Dickerson BC; Grossman M; Huey ED; Irwin DJ; Litvan I; Pantelyat AY; Tartaglia MC; Dage JL; Boxer AL
    JAMA Neurol; 2023 May; 80(5):495-505. PubMed ID: 37010841
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma Biomarker Strategy for Selecting Patients With Alzheimer Disease for Antiamyloid Immunotherapies.
    Mattsson-Carlgren N; Collij LE; Stomrud E; Pichet Binette A; Ossenkoppele R; Smith R; Karlsson L; Lantero-Rodriguez J; Snellman A; Strandberg O; Palmqvist S; Ashton NJ; Blennow K; Janelidze S; Hansson O
    JAMA Neurol; 2024 Jan; 81(1):69-78. PubMed ID: 38048096
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biomarker-Based Prediction of Longitudinal Tau Positron Emission Tomography in Alzheimer Disease.
    Leuzy A; Smith R; Cullen NC; Strandberg O; Vogel JW; Binette AP; Borroni E; Janelidze S; Ohlsson T; Jögi J; Ossenkoppele R; Palmqvist S; Mattsson-Carlgren N; Klein G; Stomrud E; Hansson O
    JAMA Neurol; 2022 Feb; 79(2):149-158. PubMed ID: 34928318
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Associations of Plasma Phospho-Tau217 Levels With Tau Positron Emission Tomography in Early Alzheimer Disease.
    Janelidze S; Berron D; Smith R; Strandberg O; Proctor NK; Dage JL; Stomrud E; Palmqvist S; Mattsson-Carlgren N; Hansson O
    JAMA Neurol; 2021 Feb; 78(2):149-156. PubMed ID: 33165506
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of Brain Tau Pathology in Down Syndrome Using Plasma Biomarkers.
    Janelidze S; Christian BT; Price J; Laymon C; Schupf N; Klunk WE; Lott I; Silverman W; Rosas HD; Zaman S; Mapstone M; Lai F; Ances BM; Handen BL; Hansson O
    JAMA Neurol; 2022 Aug; 79(8):797-807. PubMed ID: 35789365
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of Phosphorylated Tau Biomarkers With Amyloid Positron Emission Tomography vs Tau Positron Emission Tomography.
    Therriault J; Vermeiren M; Servaes S; Tissot C; Ashton NJ; Benedet AL; Karikari TK; Lantero-Rodriguez J; Brum WS; Lussier FZ; Bezgin G; Stevenson J; Rahmouni N; Kunach P; Wang YT; Fernandez-Arias J; Socualaya KQ; Macedo AC; Ferrari-Souza JP; Ferreira PCL; Bellaver B; Leffa DT; Zimmer ER; Vitali P; Soucy JP; Triana-Baltzer G; Kolb HC; Pascoal TA; Saha-Chaudhuri P; Gauthier S; Zetterberg H; Blennow K; Rosa-Neto P
    JAMA Neurol; 2023 Feb; 80(2):188-199. PubMed ID: 36508198
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer's disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study.
    Thijssen EH; La Joie R; Strom A; Fonseca C; Iaccarino L; Wolf A; Spina S; Allen IE; Cobigo Y; Heuer H; VandeVrede L; Proctor NK; Lago AL; Baker S; Sivasankaran R; Kieloch A; Kinhikar A; Yu L; Valentin MA; Jeromin A; Zetterberg H; Hansson O; Mattsson-Carlgren N; Graham D; Blennow K; Kramer JH; Grinberg LT; Seeley WW; Rosen H; Boeve BF; Miller BL; Teunissen CE; Rabinovici GD; Rojas JC; Dage JL; Boxer AL;
    Lancet Neurol; 2021 Sep; 20(9):739-752. PubMed ID: 34418401
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma P-tau181 and P-tau217 in Patients With Traumatic Encephalopathy Syndrome With and Without Evidence of Alzheimer Disease Pathology.
    Asken BM; Tanner JA; VandeVrede L; Mantyh WG; Casaletto KB; Staffaroni AM; La Joie R; Iaccarino L; Soleimani-Meigooni D; Rojas JC; Gardner RC; Miller BL; Grinberg LT; Boxer AL; Kramer JH; Rabinovici GD
    Neurology; 2022 Aug; 99(6):e594-e604. PubMed ID: 35577574
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alzheimer's cerebrospinal biomarkers from Lumipulse fully automated immunoassay: concordance with amyloid-beta PET and manual immunoassay in Koreans : CSF AD biomarkers measured by Lumipulse in Koreans.
    Moon S; Kim S; Mankhong S; Choi SH; Vandijck M; Kostanjevecki V; Jeong JH; Yoon SJ; Park KW; Kim EJ; Yoon B; Kim HJ; Jang JW; Hong JY; Park DH; Shaw LM; Kang JH
    Alzheimers Res Ther; 2021 Jan; 13(1):22. PubMed ID: 33436035
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma p-tau217 predicts in vivo brain pathology and cognition in autosomal dominant Alzheimer's disease.
    Aguillon D; Langella S; Chen Y; Sanchez JS; Su Y; Vila-Castelar C; Vasquez D; Zetterberg H; Hansson O; Dage JL; Janelidze S; Chen K; Fox-Fuller JT; Aduen P; Martinez JE; Garcia G; Baena A; Guzman C; Johnson KA; Sperling RA; Blennow K; Reiman EM; Lopera F; Quiroz YT
    Alzheimers Dement; 2023 Jun; 19(6):2585-2594. PubMed ID: 36571821
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer's disease.
    Janelidze S; Bali D; Ashton NJ; Barthélemy NR; Vanbrabant J; Stoops E; Vanmechelen E; He Y; Dolado AO; Triana-Baltzer G; Pontecorvo MJ; Zetterberg H; Kolb H; Vandijck M; Blennow K; Bateman RJ; Hansson O
    Brain; 2023 Apr; 146(4):1592-1601. PubMed ID: 36087307
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma and CSF biomarkers in a memory clinic: Head-to-head comparison of phosphorylated tau immunoassays.
    Ashton NJ; Puig-Pijoan A; Milà-Alomà M; Fernández-Lebrero A; García-Escobar G; González-Ortiz F; Kac PR; Brum WS; Benedet AL; Lantero-Rodriguez J; Day TA; Vanbrabant J; Stoops E; Vanmechelen E; Triana-Baltzer G; Moughadam S; Kolb H; Ortiz-Romero P; Karikari TK; Minguillon C; Hernández Sánchez JJ; Navalpotro-Gómez I; Grau-Rivera O; María Manero R; Puente-Periz V; de la Torre R; Roquer J; Dage JL; Zetterberg H; Blennow K; Suárez-Calvet M
    Alzheimers Dement; 2023 May; 19(5):1913-1924. PubMed ID: 36370462
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of Plasma Phosphorylated Tau Species With Amyloid and Tau Positron Emission Tomography, Neurodegeneration, Vascular Pathology, and Cognitive Outcomes.
    Mielke MM; Frank RD; Dage JL; Jeromin A; Ashton NJ; Blennow K; Karikari TK; Vanmechelen E; Zetterberg H; Algeciras-Schimnich A; Knopman DS; Lowe V; Bu G; Vemuri P; Graff-Radford J; Jack CR; Petersen RC
    JAMA Neurol; 2021 Sep; 78(9):1108-1117. PubMed ID: 34309632
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Highly accurate blood test for Alzheimer's disease is similar or superior to clinical cerebrospinal fluid tests.
    Barthélemy NR; Salvadó G; Schindler SE; He Y; Janelidze S; Collij LE; Saef B; Henson RL; Chen CD; Gordon BA; Li Y; La Joie R; Benzinger TLS; Morris JC; Mattsson-Carlgren N; Palmqvist S; Ossenkoppele R; Rabinovici GD; Stomrud E; Bateman RJ; Hansson O
    Nat Med; 2024 Apr; 30(4):1085-1095. PubMed ID: 38382645
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differences Between Plasma and Cerebrospinal Fluid Glial Fibrillary Acidic Protein Levels Across the Alzheimer Disease Continuum.
    Benedet AL; Milà-Alomà M; Vrillon A; Ashton NJ; Pascoal TA; Lussier F; Karikari TK; Hourregue C; Cognat E; Dumurgier J; Stevenson J; Rahmouni N; Pallen V; Poltronetti NM; Salvadó G; Shekari M; Operto G; Gispert JD; Minguillon C; Fauria K; Kollmorgen G; Suridjan I; Zimmer ER; Zetterberg H; Molinuevo JL; Paquet C; Rosa-Neto P; Blennow K; Suárez-Calvet M;
    JAMA Neurol; 2021 Dec; 78(12):1471-1483. PubMed ID: 34661615
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.